Single agent, adjuvant anti-PD1 therapy Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Keytruda, Nivolumab, OPDIVO®, Pembrolizumab

Filter by location:

Pittsburgh, Pennsylvania1 trial

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

UPMC Hillman Cancer Center

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.